NCT06890858View on ClinicalTrials.gov

A Clinical Study on Fasudil Hydrochloride for Treatment of Gene-Specific Ovarian Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Ovarian Cancer
Interventions
DRUG

Fasudil Hydrochloride

Exploring whether the study of using Exploring whether the study of using Fasudil Hydrochloride for the treatment of gene specific ovarian cancer can be used to predict the sensitivity of immunotherapy for non-small cell lung cancer and other tumors for the treatment of gene specific ovarian cancer can be used to predict the sensitivity of immunotherapy for non-small cell lung cancer and other tumors

Trial Locations (1)

Unknown

RECRUITING

Zhejiang Provincial People's Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Provincial People's Hospital

OTHER